BRIEF—Marinomed to resume IPO in Vienna

Vienna-based Marinomed has resumed its initial public offering and listing on the Vienna Stock Exchange. The IPO is expected to end on Tuesday 29 January 2019.

The offering comprises up to 260,000 new bearer shares, with a price range for the offered shares of 75 euros ($85) to 90 euros per share.

Among other things, the firm says the money will be used to fund a Phase III study of Budesolv (budesonide), Phase II and III studies of Tacrosolv (tacrolimus) and an extension of the Marinosolv technology for additional indications.